A clever new tuberculosis vaccine has shown promise in trials in mice. If it succeeds, it will be the first new TB vaccine in a century.
With the rise of multidrug resistant tuberculosis, the difficulty of curing the disease, and the large annual death toll, a successful vaccine could be a huge benefit to public health—especially in low- and middle income countries. The research is published January 13th in Applied and Environmental Microbiology, a journal of the American Society for Microbiology.
The vaccine uses “biobeads” as a platform to present the antigens from the tuberculosis bacterium to the immune system. These biobeads are natural polyesters that certain non-tuberculosis bacteria assemble into tiny spheres. Researchers have engineered them to display antigens from tuberculosis bacteria, Mycobacterium tuberculosis or Mycobacterium bovis. (image: mycobacterium tuberculosis Ziehl-Neelsen stain credit: CDC)
In earlier research, these investigators found that mycobacterial antigens displayed on the biobeads could induce cell-mediated immune responses in mice. Those biobeads were assembled by E.coli. “During these experiments the team observed that along with the tuberculosis antigens, E. coli proteins were attached to the surfaces of the crude biobeads,” said principal investigator Axel Heiser, PhD, Senior Scientist, AgResearch Ltd., Palmerston North, New Zealand.
“From these observations, we developed the hypothesis that these proteins could also function as antigens,” said Heiser. “If produced in Mycobacteria instead of E. coli, such biobeads should carry mycobacterial antigens on their surface, including many as yet undiscovered antigens which would have the potential to induce protective immunity.” And that, in addition to antigens from M. tuberculosis and M. bovis that they would deliberately engineer onto the biobeads, would boost immune response to the vaccine, he said.
But unlike E. coli, Mycobacteria lack the enzymes necessary to assemble biobeads, said Heiser. So they developed new cloning strategies that enabled expression of those enzymes in M. smegmatis, a mycobacterium that does not cause tuberculosis. Using M. smegmatis instead of tuberculosis-causing bacteria would avoid the possibility of the vaccine’s causing tuberculosis infection.
Following production of the biobeads, “We killed and broke up the bacteria, and purified the biobeads,” said Heiser. “They are completely natural, and have been shown to be biodegradable.”
“We then used these mycobacterial biobeads to vaccinate mice and tested the mice for immune responses,” said Heiser. “We saw evidence of cell-mediated immunity with the potential to be protective against TB. Future studies will include a vaccination followed by challenge with TB to show protection, and also the development of more efficient production and purification methods for the vaccine.”
Thus, said Heiser, mycobacterial biobeads would provide a new platform for combining a large antigenic repertoire, comparable to that of live vaccines, with high safety through the use of non-infectious material in the vaccine, including absence of any genetic material. Heiser also said that production would be cost-efficient.
In 2015, 10.4 million people contracted tuberculosis, and 1.8 million died, worldwide, according to the World Health Organization. Nearly half a million of the new cases were multidrug-resistant. 95 percent of the deaths occur in middle- and low-income countries. TB is a leading killer of people with HIV. The only existing vaccine was first used in 1921, and has a variety of shortcomings, including that it can cause the disease in immunocompromised people.
Receive an email update when we add a new TUBERCULOSIS article.
The Latest on: Multidrug resistant tuberculosis
via Google News
The Latest on: Multidrug resistant tuberculosis
- Tuberculosis Drugs Market to Surpass US$ 1,651.2 Million by 2027on September 5, 2019 at 12:00 pm
For instance, in 2015, Dishman Pharmaceuticals and Chemicals Limited entered into license collaboration with Johnson & Johnson to manufacture raw material for drugs used in the treatment of ...
- How to Get TB Patients to Take Their Pills? Persistent Texting and a ‘Winners Circle’on September 4, 2019 at 4:20 pm
In New York City in the early 1990s, for example, there was a large outbreak of multidrug-resistant tuberculosis, and dozens of victims failed or refused to take their drugs. Some were homeless or ...
- After the cheer over TB drug pretomanid, now come the challengeson August 30, 2019 at 11:20 pm
There was much cheer earlier this month when the USFDA approved pretomanid to treat some stubborn drug-resistant forms of tuberculosis ... with extensively drug-resistant TB (XDR-TB) or ...
- New medicine to counter drug-resistant Tuberculosis debutson August 19, 2019 at 7:08 pm
READ ALSO: Learning to forgive is my biggest challenge — Annie Idibia Tuberculosis affected about 10 million people in 2017. Around 558,000 cases were multidrug-resistant, unresponsive to the two most ...
- How a new antibiotic destroys extremely drug-resistant tuberculosison August 16, 2019 at 6:29 am
The trio of drugs treats extensively drug-resistant tuberculosis (XDR-TB), along with cases of multidrug-resistant tuberculosis (MDR-TB) that have proven unresponsive to other treatments. Tuberculosis ...
- FDA Approves Drug for Most Deadly Form of TBon August 15, 2019 at 9:35 am
Pretomanid tablets were approved to be used with bedaquiline and linezolid in adults with extensive multidrug-resistant tuberculosis (XDR-TB) of the lungs. Caused by a bacterium that attacks the lungs ...
- Pretomanid Approved as Part of a New Regimen for Highly Drug-Resistant Tuberculosison August 15, 2019 at 8:26 am
in combination with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis ...
- New Drug Approved for Drug-Resistant Pulmonary TBon August 14, 2019 at 12:14 pm
Pretomanid gained FDA approval for extensively drug-resistant, treatment-intolerant, or nonresponsive multidrug-resistant pulmonary tuberculosis (TB) when used in combination with bedaquiline (Sirturo ...
- FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungson August 14, 2019 at 10:06 am
M.D., Ph.D. “The bacterium that causes tuberculosis can develop resistance to the antibiotics used to treat it. Multidrug-resistant TB and extensively drug-resistant TB are public health threats due ...
via Bing News